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Background: A preliminary assessment was conducted of the feasibility, efficacy, and morbidity of 125I seed
implantation for recurrent head and neck carcinoma after surgery and external beam radiotherapy.
Methods: Nineteen patients with recurrent head and neck carcinomas underwent 125I seed implantation under
ultrasound or computed tomography guidance. The actuarial D90 of 125I seed implantation ranged from 90 to 160
Gy (median, 131 Gy). The follow-up period ranged from 3 to 44 months (median, 11 months).
Results: The median local control was 24 months (95% confidence interval, 10.2 to 37.8). The one- year, two-year
and three-year local controls were 73.3%, 27.5% and 27.5%, respectively, whereas the one-year, two-year and three-
year survival rates were 53.0%, 18.2% and 18.2%, respectively, and the median survival was 13 months (95%
confidence interval, 6.6 to 19.4). A total of 26.3% of patients (5/19) died of local recurrence and 21.1% of patients
(4/19) died of metastases. One suffered from a grade 1 skin reaction.
Conclusions: 125I seed implantation is feasible and safe as a salvage treatment for patients with recurrent head and
neck cancers. The high local control results and low morbidity merits further investigation.
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The management of local and regional recurrence after
surgery and radiotherapy in order to achieve a good out-
come is often difficult. Survival in patients with recur-
rent head and neck carcinoma remains poor in spite of
combined surgical resection and external beam radiation
therapy (EBRT), with the major cause of death still being
local and regional failure [1,2].
Many patients with local recurrence have had prior
surgery and EBRT, and further EBRT is often difficult or
impossible [3]. When a carcinoma recurs in a previously
treated field, it presents very difficult problems for man-
agement. Salvage surgery is often technically feasible;* Correspondence: doctorwangjunjie@yahoo.com.cn
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reproduction in any medium, provided the orhowever, the curative potential of surgery alone is poor
in this condition. Unfortunately, local failure in these
cases is at least 40% [4]. Re-EBRT has been used infre-
quently in the past decade because of previous high radi-
ation dosage and concern regarding limited normal
tissue tolerance. Nevertheless, local control rates of up
to 50% and a five-year survival rate of 20% have been
reported with re-EBRT [5-7]. The addition of concomi-
tant chemotherapy to re-irradiation of recurrent head
and neck carcinomas after previous full dose radiother-
apy has achieved encouraging median survivals and long
term disease-free survival [8-10].
Chemotherapy is widely used for palliation in patients
with recurrent and unresectable head and neck carcinomas
[11]. For locally advanced or recurrent head and neck can-
cer patients, temporary intraoperative high–dose-rate
(HDR) brachytherapy combined with surgery may offer an
alternative possibility, but the requirements are very high. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Characteristics of the patients (number = 19)




Median age 56(19 to 86)
Primary tumor stage
Stage I 1 5.3
Stage II 4 21.1
Stage III 7 36.8
Stage IV 7 36.8
Primary tumor
Larynx 6 31.6
Soft tissue sarcoma 3 15.8
Hypopharynx carcinoma 2 10.5
Thyroid carcinoma 2 10.5
Cancer of nasal cavities 2 10.5
Nasopharynx carcinoma 1 5.3
Submandibular gland carcinoma 1 5.3
Maxillary sinus carcinoma 1 5.3
Merkel’s cells tumor of left ear 1 5.3
Tumor pathology
Squamous cell carcinoma 9 47.4
Adenoid cystic carcinoma 2 10.5




Medullary carcinoma 1 5.3
Papillary adenocarcinoma 1 5.3
Malignant melanoma 1 5.3
Merkel’s cells tumor 1 5.3




Previous chemotherapy 5 26.3




Previous cumulative dose (Gy)
≤50 Gy 3 15.8
50 to 100 Gy 13 68.4
>100 Gy 3 15.8
Median dose(Gy) 64(34 to 14)
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implantation has also been used for salvage treatment of
recurrent head and neck carcinoma, with a 40% to 60%
local control rate and a 14% five-year survival rate [15-18].
Pulsed-dose rate (PDR) brachytherapy can offer an alter-
native re-irradiation possibility with less risk of severe
morbidity [19]. In carefully selected patients, excellent
local control rates of up to 80% with minimal side effects
have been achieved [20,21]. Unfortunately, the size and
the localization of most recurrences do not allow the opti-
mal use of interstitial therapy.
Permanent implantation of 125I seeds into the tumor
has the major advantages of delivering a high dose of
irradiation to the tumor with a very sharp fall-off outside
the implanted volume [22,23]. This concept is very im-
portant for head and neck cancers to maximize local
control and minimize morbidity [24-26]. This article in-
vestigates the feasibility and efficacy of 125I seed implant-
ation using computed tomography (CT) or ultrasound
for guidance in the management of recurrent head and
neck carcinomas and analyzes the local control and sur-
vival rates.
Methods
Patient information and selection
We retrospectively analyzed 19 patients (median age, 56
years; range, 19 to 86) who were treated with 125I seed
implantation guided by ultrasound or CT in our institu-
tion for recurrent head and neck carcinoma after surgery
and radiotherapy between January 2004 and December
2009. The criteria for eligibility were as follows: histolog-
ically proven recurrent head and neck carcinoma after
surgery and radiotherapy with no evidence of distant
metastasis; Karnofsky Performance Status (KPS) [27] of
60 or higher; and no major impairment of kidney, liver,
or bone marrow function. The diameter of the mass is
less than 9 cm. The patient characteristics are shown in
Table 1.
All patients had received radical surgery plus cervical
lymphadenectomy. Twelve patients had received surgery
once, six patients had received surgery twice, and one
patient had received surgery three times. Twelve patients
had recurrence after receiving a single course of EBRT,
whereas six patients had recurrence after receiving two
courses of EBRT. One patient had recurrence after three
courses of EBRT. The total cumulative doses ranged
from 34 to 145 Gy with 180 to 200 cGy per fraction
(median total doses, 64 Gy). Five of the nineteen patients
received a median of four cycle chemotherapy after
EBRT (range, 1 to 6). Two patients experienced a grade
2 salivary gland reaction after EBRT. Three, two and two
patients experienced a grade 1, grade 2 and grade 3 sub-
cutaneous tissue reaction after EBRT, respectively. Three
patients and one patient suffered from grade 1 and grade
Figure 1 The isodose curve distribution of tumor after seed
implantation from CT scan. The inner red curve represents tumor.
The ellipses are iso-dose lines of 200, 145, 120 and 45 Gy from
inside, respectively.
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each suffered from grade 2 and grade 3 mucous reac-
tions after EBRT, respectively. Seven patients had a re-
current carcinoma in the primary site and twelve
patients in regional lymph nodes.
All patients had been interviewed by surgeons and ra-
diation oncologists, and were considered not suitable for
salvage surgery and EBRT, whereas others refused to
undergo surgery and EBRT. The protocol was approved
by a local ethics committee and written informed con-
sent was obtained from the patients for publication of
this report and any accompanying images. The title is
“The study of dosimetry and quality control of image
guided radioactive seed implantation treatment for re-
current head and neck cancer”.
Treatment planning
All patients underwent a detailed tumor volume study
using CT scans with a 5-mm thickness one to two weeks
before seed implantation. The radiation oncologist
outlined the planning target volume (PTV) on each
transverse image. The tumor volume for the 19 patients
varied from 1 to 270 cm3, with a median of 20 cm3. The
D90 (the doses delivered to 90% of the target volume de-
fined by CT using dose-volume histograms) of irradi-
ation was determined. The total activity and the number
of 125I seeds to be implanted in the target were obtained
using the Three Dimensional Radiation Therapy Plan-
ning System (3D-TPS, Beijing Fei Tian Industries Inc.,
Beijing, China).
Interstitial brachytherapy technique
Following the administration of adequate local
anesthesia, fifteen patients underwent seed implantation
under ultrasound guidance and four patients underwent
seed implantation under CT guidance. After the direc-
tion of the needles was determination, the 18-gauge
needles were punctured into the tumor by an interven-
tional doctor, the needles kept in a parallel array with a
1.0 cm distance from each other. The direction of the
needles has to be adjusted in order to avoid the large
blood vessels and keep the needles 1 cm away from the
organ at risk. 125I seeds were implanted using a Mick ap-
plicator, and the space between seeds was maintained at
approximately 1.0 cm (center-to-center) after all needles
had been implanted into the tumor. The needles were
then removed. All patients received perioperative
prophylactic antibiotics.
Postimplant dosimetry evaluation
Postoperative dosimetry was routinely performed for all
patients. The implant dose was determined using three-
dimensional seed identification and a 5 mm thickness CT
scan immediately or 24 hours after seed implantation. Thecontored images and sources were entered into computer-
ized treatment planning system software version 3.02
(Prowess – 3D, SSGI, Norwood, Massachusetts, USA ,
and a redundancy check was performed to prevent seed
duplication. The median number of 125I seeds implanted
was 29 (range, 3 to 78). The specific activity of the 125I
seeds ranged from 0.40 to 0.80 mCi per seed, with a me-
dian of 0.67 mCi. The total amount of activity ranged
from 1.8 to 46.02 mCi, with a median of 19.6 mCi. Over
the period of total decay, the actuarial D90 was 90 to 160
Gy, with a median of 131 Gy (Figure 1 and Figure 2).
Follow-up
Tumor response was initially evaluated at four weeks and
thereafter every two to three months. Disease status was
assessed by physical examinations, liver function tests, and
complete blood and platelet counts. The presence of dis-
ease progression was determined by means of imaging
studies (CT scans and ultrasonography). The follow-up
time was calculated from the date of seed implantation.
The median follow-up was 11 months (range, 3 to 44
months). Complications were scored using the Radiation
Therapy Oncology Group (RTOG)/European Organization
for Research and Treatment of Cancer (EORTC) Late Radi-
ation Morbidity Score [28].
Statistical methods
Survival time was calculated from the date of the seed im-
plantation to the date of death or to the last follow-up.
For calculation of survival, deaths due to any reason were
Figure 2 The dose-volume histograms of gross tumor volume after seed implantation. DVH: Dose volume histogram. The DVH is showing
the target volume coverage by a certain dose level. DLV: This is the amount of the volume receiving the Defined Dose Level. D-X is defined as
the minimum dose covering X% of the target volume. V-X is defined as the percent volume of the target receiving at least X% of the prescribed
minimum peripheral dose (MPD).
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tumor progression of the implanted volume. Tumor re-
sponses were documented by CT and assessed using
World Health Organization (WHO) criteria [29]. Overall
survival curves and LC were generated using the Kaplan -
Meier method and the Statistical Package for the Social
Sciences (SPSS) 10.0 software.
Results
Local control
The overall response rate (complete response + partial
response; CR + PR) for all nineteen patients was 73.7%,
including two patients with CR (10.5%) and twelve pa-
tients with PR (63.2%). Four patients had stable disease
(SD; 21.1%), and one had progressive disease (PD; 5.3%).
The overall LC rate was 68.4% (13/19), with a median
LC time of 24 months (95% CI: 10.2 to 37.8). The one-,
two- and three- year LC rates were 73.3%, 27.5 % and
27.5%, respectively. A total of 26.3% patients (5/19) died
of local recurrence. One patient with SD died from
pneumonia three months after seed implantation, and
one patient with PD died of pneumonia eight months
after seed implantation (Figure 3).
Survival
At the time of analysis, the median survival was 13
months (95% CI, 8.70 to 15.30 months). The one-, two-and three- year actuarial overall survivals were 53.0%,
18.2% and 18.2%, respectively. The cause of death in
four patients (21.1%) who had died at the time of ana-
lysis was distant metastases (Figure 4). The patients who
died with metastatic disease were all locally controlled.Complications
One patient suffered from a grade 1 skin reaction and
another suffered from ulceration associated with tumor
progression and died of local recurrence at 11 months
after seed implantation. No soft tissue necrosis, neur-
opathy or carotid damages caused by irradiation were
noted. Furthermore, no RTOG grade 4 or 5 complica-
tions were observed.Discussion
Seed-implant brachytherapy with image-guidance has
been extensively performed in early stage prostate car-
cinoma treatment in recent years. The image-guidance
brachytherapy improves seed deposition accuracy, and
thus it delivers a sufficiently high dose to the tumor tar-
get, especially for recurrent carcinoma after EBRT. Add-
itionally, because of the low energy of the radioactive
sources of 125I, the doses to the surrounding normal tis-
sues decrease very rapidly with distance, and are easily
confined within the tumor target. Thus, seed implant
Figure 3 Kaplan-Meier estimate data showing local control for all the patients after 125I seed implantation.
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mass and spares distant normal tissues.
Radioactive isotope permanent implantation in the
management of head and neck cancer has been used for
many decades. Radium and iridium-192 have been used
for T1 and T2 patients with oral cavity and oropharynx
carcinoma, the control rates of which are very high with
functional results remaining very good [30-33]. Vikram
et al. treated 124 patients with advanced recurrent head
and neck cancer using 125I implants, 71% of whom
underwent complete regression,18% showed more thanFigure 4 Kaplan-Meier estimate data showing overall survival for all t50% regression, and 11% showed no response. Overall,
64% of the patients remained controlled until their
deaths. Only 9% of the patients survived for two years
and 5.5% survived for five years. The rate of serious com-
plications was 5.5% [34]. Goffinet et al. reported using
permanent 125I seed implants as a surgical adjuvant in the
management of advanced recurrent cancer of the head
and neck; the majority of patients in his study had re-
ceived prior treatment. Management involved a salvage
operation combined with permanent implants using
iodine-125 seeds. In this study, a 70% local control ratehe patients after 125I seed implantation.
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advanced recurrent squamous cell cancers of the head
and neck. These patients were treated with surgical resec-
tion followed by adjuvant 125I seed implants. The decision
for implantation was based upon either positive or close
margins of resection after salvage operations. The deter-
mined five-year disease-free survival was 41% [36].
Ashamalla et al. reported on 94 patients who were treated
with gold grain implants, in whom the total radiation dose
ranged from 40 to 120 Gy, with a median of 80 Gy [37].
Complete LC was achieved in 33% of patients, and palli-
ation was successfully accomplished in 76% of the cases.
Cessation of bleeding occurred in 50% of the subjects,
pain control was achieved in 88%, and 60% experienced
relief from dysphagia. Our results are similar to these find-
ings. Our results showed that the one–, two- and three-
year control rates were 73.3%, 27.5% and 27.5%, respect-
ively, with a median 24 months of local disease-free pro-
gression. The one–, two- and three-year actuarial overall
survivals were 53.0%, 18.2% and 18.2%, respectively, with
a median survival of 13 months.
Although it has been demonstrated that performing
concomitant intraoperative HDR brachytherapy enhances
actuarial survival and LC, local complications also have
also been reported, varying from 11% to 56% [36]. Marti-
nez et al. have reported an overall complication rate of
11% among 55 reconstructions performed in 48 patients
[38]. Goffinet et al. reported such complications in ap-
proximately half of their patients. The main complications
were skin ulceration and wound break-down [35]. Occa-
sionally, patients experienced carotid rupture, which can
be fatal. The key to preventing complications is a good
implant technique and the liberal use of myocutaneous
flaps for good coverage. Most interstitial brachytherapy is
performed based on preoperative images and clinical pres-
entation by placing the needles prior to treatment plan-
ning. The treatment plan is devised based on the achieved
location of the needles in the operation. Unfortunately,
the size and location of most recurrences do not allow the
optimal use of interstitial therapy. The quality of an im-
plant depends on the coverage of the PTV and the implant
geometry, enabling a homogeneous dose distribution. It is
very difficult to implant needles in parallel in tumor tar-
gets and to avoid the organ at risk. At the same time, the
complications of intraoperative implantation of 125I seeds
are high. It is difficult to define accurately the clinical tar-
get volume and the margin around the tumor under direct
vision. Further, the seeds cannot be implanted in the de-
fined volume, as any area left unimplanted will receive
very little irradiation. Further, preplanning of seed needle
implantations has a number of potential disadvantages. In
particular, alterations in organ volume and shape between
the time of the preplan and implant procedure, and the
necessity of registering the pre-implant image with theactual patient position and set-up, may introduce inaccur-
acies in the implantation process. Krempien et al. reported
the feasibility and accuracy of frameless image-guided
interstitial needle implantation for 14 patients with locally
recurrent head and neck cancers [39]. The results showed
that the one- and two-year LC rates were 78% and 57%,
respectively, and that the actuarial one- and two-year sur-
vival rates were 83% and 64%, respectively. Image guid-
ance allows virtual planning and navigated implantation of
brachytherapy needles with regard to optimized needle
distribution and risk structures. We modified the implant-
ation procedure by using CT or ultrasound guidance.
125I seed implantation with ultrasound or CT guidance
has other advantages: 1)the implant technique is
performed easily under local anesthesia without severe
pain and discomfort during hospitalization; and 2) CT
or ultrasound guidance reduces geographical miss, mini-
mizes the radiation dose to the surrounding organs due
to the sharp dose fall-off outside the implanted volume,
and enhances sublethal damage repair, thereby
protecting healthy organs from late tissue damage. We
endeavored to improve local control and decrease seque-
lae by performing seed implantation under image guid-
ance. The patients in our study were considered to have
good performance status and a reasonable expectation
of prolonged survival. We observed a very low rate of
complications. One patient suffered from a grade 1 skin
reaction, another patient suffered from an ulcer as a re-
sult of tumor progression and died of local recurrence
11 months after seed implantation. No bone, soft tissue
necrosis or carotid artery damages were noted.
Conclusion
CT or ultrasound-guided interstitial permanent 125I seed
implantation is an effective re-irradiation modality for
recurrent head and neck carcinomas after surgery and
EBRT. It avoids the morbidity associated with further
surgery or EBRT, achieves good local control, and the
side effects are minimal. However, considering the small
number of patients and the short follow-up period, a
definite conclusion will require a larger number of pa-
tients and follow-up over a longer term.
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